Insmed Q4 2022 Earnings Report
Key Takeaways
Insmed reported a strong finish to 2022 with significant commercial and clinical execution. Screening is complete in adult patients in the Phase 3 ASPEN study of brensocatib in bronchiectasis, with topline results expected in the second quarter of 2024. ARIKAYCE global revenue grew 30% in 2022 compared to 2021.
ARIKAYCE global revenue grew 30% in 2022, driven by strong U.S. performance, the ongoing launch in Japan, and contributions from European markets.
Patient screening is complete in adult patients in the Phase 3 ASPEN study of brensocatib in bronchiectasis, with topline data expected in the second quarter of 2024.
Insmed anticipates sharing topline efficacy and safety data from the ARISE study in the third quarter of 2023 and completing enrollment in the ENCORE study by the end of 2023.
Insmed plans to provide an update on its early-stage research portfolio on May 8, 2023, and anticipates having at least six IND applications filed or Phase 1 studies underway by the end of 2025.
Insmed
Insmed
Forward Guidance
Insmed expects full-year 2023 global revenues for ARIKAYCE to be between $285 million and $300 million and anticipates over 80% of total expenditures will be on its mid-to-late stage and commercial programs.
Positive Outlook
- Commercialization and expansion of ARIKAYCE globally
- Advancement of brensocatib, including the Phase 3 ASPEN study
- Development across additional neutrophil-mediated diseases
- Advancement of the confirmatory, frontline clinical trial program for ARIKAYCE (ARISE and ENCORE)
- Advancement of its earlier-stage pipeline, including the Phase 2 clinical development programs for TPIP and development of its early-stage research platforms